Clinical trials: Hepatocellular
Bladder Cancer, Cervical Cancer
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
RATIONALE: Stop-smoking plans, including counseling and nicotine replacement therapy, may help smokers quit smoking. It is not yet known whether counseling and the nicotine lozenge is more effective than counseling and the…
- Conditions
- Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT00365508
- Testing
- nicotine lozenge, nicotine patch
- Where
- 10 sites in United States
- Volunteers
- 642 people
- Sponsor
- Fox Chase Cancer Center
Hepatocellular Carcinoma
Phase II Trial of SOM230 in Patients With Unresectable Hepatocellular Carcinoma
The hypothesis of this clinical trial is that hepatocellular carcinomas contain somatostatin receptors which make them sensitive to the inhibitory effects of a new somatostatin analog, SOM230.
- Trial name
- NCT01639352
- Testing
- SOM230
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Lynn Feun
Carcinoma, Hepatocellular
A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100)
To evaluate the safety, efficacy and PK of avelumab in combination with axitinib as first line treatment in patients with advanced HCC
- Trial name
- NCT03289533
- Testing
- Avelumab (MSB0010718C), Axitinib (AG-013736)
- Where
- 7 sites in Japan
- Volunteers
- 22 people
- Sponsor
- Pfizer
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
Doxorubicin and Bortezomib in Treating Patients With Liver Cancer
This phase II trial is studying how well giving doxorubicin together with bortezomib works in treating patients with liver cancer.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT00083226
- Testing
- doxorubicin, bortezomib
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Cancer
Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer
The purpose of this research study is to determine if sorafenib improves the effectiveness of a procedure called radiofrequency ablation (RFA) for the treatment of hepatocellular cancer (HCC).
- Trial name
- NCT00813293
- Testing
- Sorafenib, radiofrequency ablation
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Beth Israel Deaconess Medical Center
Liver Cancer, Hepatocellular Cancer
A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer
This phase II trial is studying how well giving oxaliplatin and capecitabine together works in treating patients with liver cancer.
- Trial name
- NCT03026803
- Testing
- Oxaliplatin, Capecitabine
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- City of Hope Medical Center
Carcinoma, Hepatocellular
Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma
This is a randomized trial to evaluate the clinical benefit of sorafenib 400 mg twice daily and erlotinib 150 mg once a day versus sorafenib 400 mg twice daily and placebo erlotinib once daily in subjects with unresectable…
- Trial name
- SEARCH (NCT00901901)
- Testing
- Sorafenib (Nexavar, BAY43-9006), Erlotinib (Tarceva)
- Where
- 127 sites in United States, Australia and 24 more
- Volunteers
- 732 people
- Sponsor
- Bayer
Gastric Cancer, Hepatocellular Carcinoma
Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma
This is a phase II, single arm, open-label study of two parallel cohorts (advanced stomach and gastroesophageal junction cancer and hepatocellular carcinoma), evaluating the effects of telatinib in combination with Keytruda on…
- Trial name
- NCT04798781
- Testing
- Telatinib, Keytruda
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- Andrew Hendifar, MD
Hepatocellular Carcinoma
LEE001 and Chemoembolization In Patients With Advanced Hepatocellular Carcinoma
The purpose of this study is determine whether the combination therapy with LEE011 and chemoembolization in patients with locally advanced Hepatocellular Carcinoma not amenable to curative therapies will provide greater efficacy…
- Trial name
- LEE001 (NCT02524119)
- Testing
- LEE011, Chemoembolization
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Texas Southwestern Medical Center
Hepatocellular Carcinoma
Study of Anti-tumour Effects and Safety of Prolarix™ in Hepatocellular Carcinoma
This an open-label study designed to evaluate the anti-tumour activity and safety of Prolarix in subjects with advanced hepatocellular carcinoma.
- Trial name
- NCT00746590
- Testing
- Prolarix (tretazicar co-administered with caricotamide)
- Where
- Belgium
- Volunteers
- 1 people
- Sponsor
- BTG International Inc.
Liver Cirrhosis, Hepatocellular Carcinoma
Safety Study of Liver Natural Killer Cell Therapy for Hepatoma Liver Transplantation
The objective of this study is to evaluate feasibility and safety of the adoptive transfer of activated natural killer (NK) cells extracted from cadaveric donor liver graft perfusate for liver transplant recipients with…
- Conditions
- Liver Cirrhosis, Hepatocellular Carcinoma, Evidence of Liver Transplantation
- Trial name
- MIAMINK (NCT01147380)
- Testing
- Liver NK cell inoculation
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Seigo Nishida
Advanced Cancer, Gastric Adenocarcinoma
A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer
The purpose of this study is to find a recommended schedule and dose range for Emibetuzumab when given with ramucirumab that may be safely given to participants with cancer.
- Conditions
- Advanced Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Hepatocellular Cancer
- Trial name
- NCT02082210
- Testing
- Emibetuzumab, Ramucirumab
- Where
- 4 sites in United States
- Volunteers
- 97 people
- Sponsor
- Eli Lilly and Company
Hepatocellular Carcinoma (HCC)
A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma
E7080-G000-304 is a multicenter, randomized, open-label, noninferiority Phase 3 study to compare the efficacy and safety of lenvatinib versus sorafenib as a first-line systemic treatment in participants with unresectable…
- Trial name
- NCT01761266
- Testing
- Lenvatinib, Sorafenib
- Where
- 186 sites in United States, Australia and 19 more
- Volunteers
- 954 people
- Sponsor
- Eisai Limited
Advanced Hepatocellular Carcinoma, Liver Cancer
CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer
The purpose of this study is to determine the safety and efficacy of CS-1008 in combination with sorafenib to sorafenib alone for treating liver cancer.
- Conditions
- Advanced Hepatocellular Carcinoma, Liver Cancer, Hepatic Cancer, Liver Neoplasms
- Trial name
- NCT01033240
- Testing
- CS-1008 2 mg/kg, Sorafenib, CS-1008 6/2 mg/kg
- Where
- 28 sites in United States, Japan and 2 more
- Volunteers
- 172 people
- Sponsor
- Daiichi Sankyo
Breast Cancer, Lung Cancer
Study of Pazopanib and Ixabepilone in Patients With Solid Tumors
This is a Phase I study; dose escalating the combination of pazopanib when taken daily and ixabepilone when administered on day 1 of a 3 week treatment course.
- Conditions
- Breast Cancer, Lung Cancer, Colon Cancer, Pancreatic Cancer
- Trial name
- NCT01012362
- Testing
- Pazopanib, Ixabepilone
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Hepatocellular Cancer
HCV-RNA Kinetics During Sorafenib for Hepatocellular Carcinoma (HCC)
This research study is a Phase IV clinical trial. Phase IV trials are used to further test and monitor the safety of a drug approved by the FDA and to see if the drug has any other indications that can be used to treat different…
- Trial name
- NCT01849588
- Testing
- Sorafenib
- Where
- 3 sites in United States
- Volunteers
- 3 people
- Sponsor
- Massachusetts General Hospital
Hepatocellular Cancer
Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer
The purpose of this study is to learn about the effect of the investigational agent tivozanib on the control of the tumor growth in hepatocellular (liver) cancer.
- Trial name
- NCT01807156
- Testing
- Tivozanib
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Emory University
AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
This phase I trial studies the side effects of pembrolizumab in treating patients with human immunodeficiency virus (HIV) and malignant neoplasms that have come back (relapsed), do not respond to treatment (refractory), or have…
- Conditions
- AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hepatocellular Carcinoma
- Trial name
- NCT02595866
- Testing
- Antiretroviral Therapy, Biopsy, Biospecimen Collection
- Where
- 12 sites in United States
- Volunteers
- 58 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Hepatocellular Carcinoma
Itacitinib in Advanced Hepatocellular Carcinoma
This research will assess the effects of Itacitinib as a second line treatment for patients with advanced inflammatory hepatocellular carcinoma (HCC), a type of liver cancer.
- Trial name
- JAKaL (NCT04358185)
- Testing
- Itacitinib
- Where
- United Kingdom
- Volunteers
- 19 people
- Sponsor
- Imperial College London
Carcinoma, Hepatocellular
A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC)
CC-122-HCC-002 is a Phase 1/2 dose escalation and expansion clinical study of CC-122 in combination with nivolumab in subjects with unresectable hepatocellular carcinoma (HCC) who have progressed after or were intolerant to no…
- Trial name
- NCT02859324
- Testing
- CC-122, Nivolumab
- Where
- 14 sites in United States, France and 2 more
- Volunteers
- 21 people
- Sponsor
- Celgene